Trexquant Investment LP Trims Stake in AngioDynamics, Inc. (NASDAQ:ANGO)

Trexquant Investment LP cut its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 70.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 81,771 shares of the medical instruments supplier’s stock after selling 198,494 shares during the quarter. Trexquant Investment LP’s holdings in AngioDynamics were worth $749,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Segall Bryant & Hamill LLC lifted its position in AngioDynamics by 55.3% in the fourth quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier’s stock valued at $12,963,000 after buying an additional 503,713 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of AngioDynamics by 293.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 352,544 shares of the medical instruments supplier’s stock worth $3,229,000 after acquiring an additional 263,034 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of AngioDynamics by 46.0% during the 4th quarter. JPMorgan Chase & Co. now owns 807,483 shares of the medical instruments supplier’s stock worth $7,397,000 after purchasing an additional 254,322 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in AngioDynamics by 69.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 389,053 shares of the medical instruments supplier’s stock valued at $3,564,000 after purchasing an additional 158,897 shares during the last quarter. Finally, Royce & Associates LP raised its position in AngioDynamics by 13.5% in the fourth quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock valued at $10,254,000 after purchasing an additional 133,312 shares during the period. 89.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target (up from $15.00) on shares of AngioDynamics in a research report on Monday.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares of the company’s stock, valued at $514,767.27. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.40% of the stock is currently owned by company insiders.

AngioDynamics Stock Performance

Shares of ANGO opened at $9.29 on Friday. The company’s 50-day simple moving average is $9.80 and its 200-day simple moving average is $8.95. AngioDynamics, Inc. has a 1 year low of $5.47 and a 1 year high of $13.50. The stock has a market capitalization of $377.24 million, a PE ratio of -1.65 and a beta of 0.52.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.16. The company had revenue of $72.00 million for the quarter, compared to analyst estimates of $70.30 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm’s revenue for the quarter was down 4.3% on a year-over-year basis. On average, sell-side analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.